

Orthocell Strengthens Executive Leadership Team with Two Senior Appointments

- Orthocell has strengthened its leadership team with the appointment of two highly experienced senior executives in Jim Piper as Chief Financial Officer and Adam Wood as Chief Commercial Officer.
- The appointments appropriately position the Company against the backdrop of rapidly growing revenue and the ramp up of market engagement and product sales in the United States and other key international markets.
- Orthocell remains focused on driving the continued sales momentum and establishing Remplir™ as a leading solution in a global addressable nerve repair market estimated to be worth in excess of US\$3.5 billion¹.

Perth, Australia; 2 July 2025: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is delighted to announce the appointment of two senior executives to its leadership team. The appointments support the Company’s global expansion and commercialisation activities for its groundbreaking regenerative medicine product portfolio, and most notably its flagship nerve repair device, Remplir™.

Mr Jim Piper, joining Orthocell as Chief Financial Officer (CFO), brings extensive experience in strategic finance and operational execution across ASX-listed and high-growth companies. As CFO, Mr Piper will oversee financial management and governance initiatives to maximise financial performance and shareholder value. In addition to his responsibilities as CFO, Mr. Piper will also oversee Investor Relations, Procurement, and Information Technology functions. Mr Piper’s prior experience includes senior financial roles at Pilbara Minerals, where he led financial planning and analysis for corporate, operations, capital and modelling functions across major planning cycles. He also held a leadership role at global consulting firm Accenture within the CFO Strategy and Consulting practice, advising major organisations on financial transformation, performance optimisation, and digital initiatives. Prior to his career in finance, Mr Piper was an accomplished professional athlete. He represented Australia as a member of the swimming team at the 2004 Athens Olympic Games and won two gold medals at the 2002 Commonwealth Games. He will commence employment with Orthocell on 1 August 2025.

Mr Piper will undertake the role as CFO after Ms Nicole Telford’s over 15-year tenure, during which time she played a pivotal role in the establishment and expansion of Orthocell’s finance function, and its impressive growth curve. Ms Telford commenced as Company Accountant, progressed to Financial Controller and was ultimately appointed CFO during her time with Orthocell. She will be available as a part time advisor for up to six months to ensure a smooth transition. The Board would like to formally acknowledge Ms Telford’s enormous contributions and wish her well for future endeavours.

Mr Adam Wood has been appointed to the newly created role of Chief Commercial Officer (CCO) to oversee

¹ Company estimate of addressable market size for Remplir (AUS, NZ, SGP, USA, EU/UK, CAN, BRZ, JAP & THA). Sources include iData Research Inc and other publicly available market research reports and published literature.



the global sales and marketing of Orthocell's product portfolio. Mr Wood will drive Orthocell's business development and sales rollout in key global markets, focussing on the US, and lead the worldwide commercialisation of Orthocell's intellectual property portfolio. Mr Wood brings extensive experience in sales and marketing in the healthcare and medical technology sectors, having previously held senior roles at Johnson & Johnson, LifeHealthcare and most recently EBOS Medical Technology (part of EBOS Group), where he led brand strategy, product marketing and corporate development as Executive General Manager. Prior to that Mr. Wood held the role of General Manager, Marketing at Life Healthcare, where, under private equity ownership, he led the expansion of the marketing capabilities in line with the growth of the business (>4 x EBITDA in four years) by attracting high calibre talent and lifting team engagement scores from 58% to 85%.

Orthocell Chairman, John Van Der Wielen, said: "I would like to acknowledge and thank Nicole Telford for her commitment and contributions over the last 15 years. She has been a highly valued member of our team, as we grew from humble beginnings, and leaves as a deeply valued Orthocell ally. We wish her all the very best.

I am also excited to welcome our two new executives, Jim Piper as Chief Financial Officer and Adam Wood to the newly created role of Chief Commercial Officer. They both bring outstanding experience to the Company which will be invaluable as we extend the commercialisation of our products, particularly Remplir™ in the US. I anticipate that they will play significant roles in driving our Company forward."

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD

P: +61 8 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Haley Chartres
HACK Director

P: +61 423 139 163

E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors

P: +61 404 094 384

E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia



Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed 14 US distributors, with first sales expected to follow shortly. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore and is distributed exclusively by Device Technologies Group. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

